Spots Global Cancer Trial Database for Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
Official Title: A Phase II Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of Maintenance IT-101 in Platinum Sensitive Ovarian Cancer Patients Who Received 4-6 Cycles of a 2nd Line Platinum-Based Regimen Without Disease Progression.
Study ID: NCT00753740
Study Description
Brief Summary: This study will assess the effect of IT-101 on delaying cancer progression in patients with platinum sensitive ovarian cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Decatur Memorial Hospital, Clinical Research Department/ Cancer Care Specialists of Illinois, Decatur, Illinois, United States
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Schwartz Gynecologic Onclology, PLLC, Brightwaters, New York, United States
Gabrail Cancer Center, Canton, Ohio, United States
Chattanooga GYN Oncology, Chattanooga, Tennessee, United States
The Methodist Hospital, Houston, Texas, United States
Riverside Gynecology & Oncology, Newport News, Virginia, United States
Contact Details
Name: Jonathan S Berek, MD, MMS
Affiliation: Professor and Chair, Department of Obstetrics and Gynecology Stanford University School of Medicine Stanford Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: Franco Muggia, MD
Affiliation: Anne Murnick Cogan and David H. Cogan Professor of Oncology, Director of the Division of Medical Oncology at NYU Medical Center, and Associate Director for Clinical Research
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
